Fetal hemoglobin synthesis pathway

The **fetal hemoglobin synthesis pathway** refers to the coordinated molecular processes that produce fetal hemoglobin (**hemoglobin F**, or **HbF**), which is composed of two alpha and two gamma globin chains. This form predominates during fetal life, ensuring efficient oxygen delivery from mother to fetus. After birth, a developmental switch occurs where gamma globin production declines while beta globin increases, leading to the predominance of adult hemoglobin (**hemoglobin A**) within several months after birth[1][5]. Regulation involves complex transcriptional control at the β-globin locus, including key factors such as BCL11A and LCR interactions that silence or activate γ-globin genes depending on developmental stage. Disruption or manipulation of these regulatory elements can reactivate HbF production in adults—a therapeutic strategy for diseases like sickle cell disease and β-thalassemia where increased HbF ameliorates symptoms by compensating for defective adult β-globin chains[2][3][6]. Pharmacologic agents such as hydroxyurea induce this pathway by promoting γ-globin gene expression; newer approaches include epigenetic drugs and CRISPR/Cas9-based genome editing targeting repressors like BCL11A or specific silencer regions within the locus control region (LCR)[2][3]. Monitoring therapy often relies on measuring %HbF or γ-globin mRNA. This entry is not a single molecule but rather a biological process/pathway involving multiple genes, proteins, enzymes, transcription factors, and regulatory DNA elements. Therefore it should not be considered a canonical "target" like an enzyme or receptor; instead individual components—such as BCL11A protein—are more appropriate therapeutic targets within this context[6].

Other names

Hemoglobin F synthesis pathwayHbF synthesis pathwayγ-globin gene regulation pathwayFetal globin expression pathway

Induction of γ-globin gene expression, increasing HbF levels in erythrocytes